We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the ...

10x Genomics (Nasdaq: NASDAQ:TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation ...

OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and ...

10x Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in the United States District Court for the District of ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the life science tools and diagnostics group post the ...

Detailed price information for 10X Genomics Inc (TXG-Q) from The Globe and Mail including charting and trades.